Allogeneic hematopoietic stem cells transplantation with reduced intensity conditioning regimen in children and adolescents with unfavorable forms of acute lymphoblastic leukemia

Treatment results of allogeneic hematopoietic stem cells transplantation (allo-HSCT) with myeloablative (MAC) and reduced intensity (RIC) conditioning regimen in children and adolescents with unfavorable forms of acute lymphoblastic leukemia (ALL) were shown. One hundred and two ALL patients aged 1 to 21 years (mean – 12 years) who received allo-HSCT from 2000 to 2010 (31 patients with RIC and 71 patients with MAC) are included in the study. Analysis of overall and event-free survival in both groups showed comparable efficacy. The use of RIC as alternative conditioning regimen in children and adolescents with high risk ALL and poor general condition, comorbidities and infectious complications are discussed.

1. Eden T., Pui C.H., Schrappe M. et al. All children have a right to full access to treatment for cancer. Lancet 2004;364(9440):1121–2.

2. Pui C.H., Evans W.E. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354(2):166–78.

3. Chessells J.M., Veys P., Kempski H. et al. Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia. Br J Haematol 2003;123:396–405.

4. Nguyen K., Devidas M., Cheng S.C. et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: A Children’s Oncology Group study. Leukemia 2008;22:2142–50.

5. Афанасьев Б.В., Зубаровская Л.С. Трансплантация гемопоэтических стволовых клеток крови. Детская онкология. Руководство. СПб., 2002. С. 90–108.

6. Румянцев А.Г., Масчан А.А. Трансплантация гемопоэтических стволовых клеток у детей. Руководство для врачей. М., 2003.

7. Kenney L.B., Nancarrow C.M., Najita J. et al. Health status of the oldest adult survivors of cancer during childhood. Cancer 2010;15:497–506.

8. Sundberg K.K., Doukkali E., Lampic C. et al. Long-term survivors of childhood cancer report quality of life and health status in parity with a comparison group. Pediatr Blood Cancer 2010;55:337–43.

9. Abou-Mourad Y.R., Lau B.C., Barnett M.J. et al. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Bone Marrow Transplantation 2010;45:295–302.

10. Slavin S., Nagler A. et al. Shifting towards better immunotherapy rather than more intensive chemoradiotherapy using a nonmyeloablative approach in patients with leukemia. In: Buchner T., Hiddemann W., Wormann B., Schellong G., Ritter J., Creutzig U. Acute leukemias. Prognostic factors and treatment strategies. Berlin: Springer, 1999; pp. 674–677.

11. Giralt S., Estey E., Albitar M. et al. Engraftment of allogeneic hematopoetic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versusleukemia without myeloablative therapy. Blood 1997;89(12):4531–6.

12. Champlin R. Nonmyeloablative chemotherapy with allogeneic hematopoietic transplantation as adoptive immunotherapy for malignancies. Hematology 1999:413–6.

13. Storb R.F., Champlin R., Riddell S.R. et al. Non-myeloablative transplants for malignant disease. Hematology 2001:375–91.

14. Kolb H.J., Schattenberg A. et al. Graftversusleukemia effect of donor lymphocyte transfusion in marrow grafted patients. Blood 1995;86:2041–4.

15. Weiden P.L., Sullivan K.M., Flournoy N. et al. Antileukemic effect of chronic graftversus- host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981;304:1529–31.

16. Sullivan K.M., Storb R., Buckner C.D. et al. Graft-versus-host-disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989;320:828–33.

17. Mohty M., Labopin M., Tabrizzi R. et al. Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation Haematologica 2008;93(2):303–6.

18. Bachanova V., Verneris M.R., DeFor T. et al. Prolonged survival in adults with acute lymphoblastic leukemia after reducedintensity conditioning with cord blood or sibling donor transplantation. Blood 2009;26;113 (13):2902–5.

19. Pulsipher M.A., Boucher K.M., all D. et al. Redused-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. Blood 2009;114:1429–36.

20. Verneris M.R., Eapen M., Duerst R. et al. Redused-Intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia. Biol BloodMarrow Transplant 2010:1–8.

21. Horowitz M., Gale R.P., Sondel P.M.,Goldman J.M. et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75;555–62.

22. Stackelberg A., Volzke E., Kuhl J.-S. et al. Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group. Eur J Cancer 2011;47(1):90–7.

23. Michallet M., Bilger K., Garban F. et al. Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact ofpretrans plantation and posttransplantation factors on outcome. J Clin Oncol 2001;19(14):3340–9.